Infinium Pharmachem Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Sanjaykumar Patel
Chief executive officer
₹6.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.3yrs |
| CEO ownership | n/a |
| Management average tenure | 8.3yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
Investors Still Aren't Entirely Convinced By Infinium Pharmachem Limited's (NSE:INFINIUM) Earnings Despite 38% Price Jump
Sep 20
Many Still Looking Away From Infinium Pharmachem Limited (NSE:INFINIUM)
Aug 04Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues
Jun 12Infinium Pharmachem (NSE:INFINIUM) Strong Profits May Be Masking Some Underlying Issues
Nov 06CEO
Sanjaykumar Patel (45 yo)
2.3yrs
Tenure
₹6,100,000
Compensation
Mr. Sanjaykumar Viththalbhai Patel serves as Chairman and Managing Director of Infinium Pharmachem Private Limited since October 14, 2022. He serves as Director of Infinium Pharmachem Private Limited since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 2.3yrs | ₹6.10m | no data | |
| CFO, Company Secretary and Compliance Officer | 1.3yrs | ₹3.50m | no data | |
| Whole Time Director | 21.3yrs | ₹6.10m | no data | |
| Whole Time Director | 14.3yrs | ₹6.10m | no data |
8.3yrs
Average Tenure
45yo
Average Age
Experienced Management: INFINIUM's management team is seasoned and experienced (8.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 21.3yrs | ₹6.10m | no data | |
| Whole Time Director | 21.3yrs | ₹6.10m | no data | |
| Whole Time Director | 14.3yrs | ₹6.10m | no data | |
| Non-Executive Independent Director | 2.3yrs | ₹40.00k | no data | |
| Non-Executive Independent Director | 2.3yrs | ₹40.00k | no data | |
| Non-Executive Independent Director | 2.3yrs | ₹40.00k | no data |
8.3yrs
Average Tenure
44.5yo
Average Age
Experienced Board: INFINIUM's board of directors are considered experienced (8.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 22:31 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Infinium Pharmachem Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|